GENERAL INQUIRIES

OUR LOCATION

  • 520 US Highway 22
  • Suite 201
  • Bridgewater, NJ 08807
  • View Map
  •  
  • P: 908.895.1200
  • F: 908.895.1201

SPECIFIC INQUIRIES

Our Current Pipeline

ASP7035 for Nocturia

ASP7035 is a novel, small molecule, selective vasopressin 2 receptor agonist that will be evaluated in a Phase 2 clinical study for the treatment of nocturia. ASP7035 mimics the action of the natural agent, arginine vasopressin, and regulates renal water excretion.

Nocturia is defined as the need for individuals to wake at night one or more times to void urine. Nocturia may produce a range of detrimental effects because of associated sleep fragmentation experienced by patients on a regular basis, including: reduced health-related quality of life, mood disturbance, reduced productivity at work, poorer overall health, and increased falls and fractures.

Drais Pharmaceuticals, Inc. is developing ASP7035 for Tacurion through an exclusive relationship, which is funded by InterWest Partners, Sutter Hill Ventures and Astellas Venture Management, LLC.

ASP7147 for Diarrhea-Predominant Irritable Bowel Syndrome

ASP7147 is a novel, small molecule Bombesin-2 receptor antagonist. Seldar has completed Phase 1 and Phase 2 clinical studies in the United States. Activation of the Bombesin-2 receptor may be important in the regulation of gastrointestinal motility and intestinal secretion. ASP7147-mediated inhibition of this receptor and the processes it controls has the potential to improve symptoms in patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).

IBS-D is a common disorder that is associated with cramping, abdominal pain, and diarrhea. These symptoms probably represent disturbances in the interaction between the gut or intestines, the brain, and enteric or autonomic nervous systems and regulation of bowel motility and sensory function.

Drais Pharmaceuticals, Inc. is developing this drug for Seldar through an exclusive relationship, which is funded by InterWest Partners, Sutter Hill Ventures and Astellas Venture Management, LLC.